Neuronetics Inc
STIM1.400USD
-0.015-1.06%
收盘 12/19, 16:00（美东）报价延迟15分钟
95.82M总市值
亏损市盈率 TTM
关于 Neuronetics Inc 公司
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Neuronetics Inc简介
公司代码STIM
公司名称Neuronetics Inc
上市日期Jun 28, 2018
CEOMr. Keith J. Sullivan
员工数量716
证券类型Ordinary Share
年结日Jun 28
公司地址3222 Phoenixville Pike
城市MALVERN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编19355
电话18776007555
网址https://neurostar.com/neuronetics/
公司代码STIM
上市日期Jun 28, 2018
CEOMr. Keith J. Sullivan
Neuronetics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+0.32%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+1.82%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
400.00K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+2.30%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+4.12%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+27.05%
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+0.32%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+1.82%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
400.00K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+2.30%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+4.12%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+27.05%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Clinic revenue
23.02M
60.42%
Treatment sessions
11.05M
29.00%
NeuroStar Advanced Therapy System
3.65M
9.57%
Other
385.00K
1.01%
地区USD
名称
营收
占比
United States
37.66M
98.81%
International
452.00K
1.19%
业务
地区
业务USD
名称
营收
占比
Clinic revenue
23.02M
60.42%
Treatment sessions
11.05M
29.00%
NeuroStar Advanced Therapy System
3.65M
9.57%
Other
385.00K
1.01%
股东统计
更新时间: 11月26日 周三
更新时间: 11月26日 周三
持股股东
股东类型
持股股东
持股股东
占比
Madryn Asset Management, LP
30.28%
Chernett (Jorey)
6.43%
The Vanguard Group, Inc.
4.14%
UBS Financial Services, Inc.
3.16%
BlackRock Institutional Trust Company, N.A.
3.10%
其他
52.90%
持股股东
持股股东
占比
Madryn Asset Management, LP
30.28%
Chernett (Jorey)
6.43%
The Vanguard Group, Inc.
4.14%
UBS Financial Services, Inc.
3.16%
BlackRock Institutional Trust Company, N.A.
3.10%
其他
52.90%
股东类型
持股股东
占比
Private Equity
30.28%
Individual Investor
15.58%
Investment Advisor
13.62%
Hedge Fund
9.59%
Investment Advisor/Hedge Fund
6.10%
Research Firm
1.71%
Bank and Trust
0.11%
Pension Fund
0.05%
Venture Capital
0.04%
其他
22.92%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
198
39.45M
57.60%
-13.65M
2025Q2
187
47.56M
71.93%
-4.03M
2025Q1
191
47.19M
71.70%
-4.84M
2024Q4
155
36.70M
70.38%
+11.74M
2024Q3
153
14.58M
47.42%
-9.85M
2024Q2
159
20.22M
66.61%
-5.87M
2024Q1
183
20.38M
68.24%
-3.49M
2023Q4
191
18.37M
63.28%
-7.87M
2023Q3
201
19.69M
68.24%
-8.69M
2023Q2
222
21.10M
73.37%
-11.20M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Madryn Asset Management, LP
20.74M
31.36%
-3.50M
-14.44%
Aug 08, 2025
The Vanguard Group, Inc.
2.74M
4.15%
+436.54K
+18.93%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.05M
3.1%
+1.67M
+440.36%
Jun 30, 2025
Cucuz (Sasha)
2.02M
3.06%
+30.00K
+1.50%
May 22, 2025
Balyasny Asset Management LP
1.51M
2.28%
+92.05K
+6.50%
Jun 30, 2025
Sullivan (Keith J)
1.61M
2.43%
--
--
Mar 24, 2025
Wexford Capital LP
643.07K
0.97%
+171.34K
+36.32%
Jun 30, 2025
Masters Capital Management, L.L.C.
1.00M
1.51%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
AdvisorShares Psychedelics ETF
3.31%
Invesco NASDAQ Future Gen 200 ETF
0.43%
iShares Neuroscience and Healthcare ETF
0.1%
Vanguard US Momentum Factor ETF
0.04%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.01%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
查看更多
AdvisorShares Psychedelics ETF
占比3.31%
Invesco NASDAQ Future Gen 200 ETF
占比0.43%
iShares Neuroscience and Healthcare ETF
占比0.1%
Vanguard US Momentum Factor ETF
占比0.04%
iShares Micro-Cap ETF
占比0.02%
iShares Russell 2000 Growth ETF
占比0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.01%
Avantis US Small Cap Equity ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Proshares Ultra Russell 2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Neuronetics Inc的前五大股东是谁？
Neuronetics Inc 的前五大股东如下：
Madryn Asset Management, LP持有股份：20.74M，占总股份比例：31.36%。
The Vanguard Group, Inc.持有股份：2.74M，占总股份比例：4.15%。
BlackRock Institutional Trust Company, N.A.持有股份：2.05M，占总股份比例：3.10%。
Cucuz (Sasha)持有股份：2.02M，占总股份比例：3.06%。
Balyasny Asset Management LP持有股份：1.51M，占总股份比例：2.28%。
Madryn Asset Management, LP持有股份：20.74M，占总股份比例：31.36%。
The Vanguard Group, Inc.持有股份：2.74M，占总股份比例：4.15%。
BlackRock Institutional Trust Company, N.A.持有股份：2.05M，占总股份比例：3.10%。
Cucuz (Sasha)持有股份：2.02M，占总股份比例：3.06%。
Balyasny Asset Management LP持有股份：1.51M，占总股份比例：2.28%。
Neuronetics Inc的前三大股东类型是什么？
Neuronetics Inc 的前三大股东类型分别是：
Madryn Asset Management, LP
Chernett (Jorey)
The Vanguard Group, Inc.
Madryn Asset Management, LP
Chernett (Jorey)
The Vanguard Group, Inc.
有多少机构持有Neuronetics Inc(STIM)的股份？
截至2025Q3，共有198家机构持有Neuronetics Inc的股份，合计持有的股份价值约为39.45M，占公司总股份的57.60%。与2025Q2相比，机构持股有所增加，增幅为-14.33%。
哪个业务部门对Neuronetics Inc的收入贡献最大？
在FY2025Q2，Clinic revenue业务部门对Neuronetics Inc的收入贡献最大，创收23.02M，占总收入的60.42%。
